Journal of Clinical and Cellular Immunology
Open Access
ISSN: 2155-9899
+44 1223 790975
ISSN: 2155-9899
+44 1223 790975
Mohammad Hossein Yazdi
Tehran University of Medical Sciences, Iran
Posters & Accepted Abstracts: J Clin Cell Immunol
Background: Induction of cellular immune response in tumor bearing mice and decrease of suppressor factors may result
in controlling and inhibition of tumor progression. In the present study, after immunization with HPV17E7d vaccine
using BCG bacteria as adjuvant in tumor bearing mice, the balance of inflammatory and anti-inflammatory cytokines was
assessed.
Material and Methods: Tumor was established in C57BL/6 mice with transplantation method. Experimental C57BL/6
tumor bearing mice were vaccinated three times with 10 days intervals with E7d protein formulated in Alum and BCG
vaccine adjuvants. One week after final immunization, serum samples were obtained from five mice in each group. Then
the quantity of IL-4, INF-γ, TNF-α cytokines and total IgG Antibody were evaluated with commercial ELISA kits. Also,
the level of IgG1 and IgG2a were measured. In addition, survival and volume of tumors were monitored during the study
period.
Result: Results showed that immunization with vaccine formulated in BCG as adjuvant increased INF-γ and its ratio to
IL-4. Also, TNF-&alpha and total Antibody level were significantly higher when compared to PBS control and E7d Alum vaccine
groups. In addition, survival of vaccinated mice with BCG adjuvant showed longer lifespan and the tumor volume of mice
in this group were significantely lower than others.
Conclusion: Regarding to the present sata it can be concluded that formulation of E7d vaccine in BCG Alum can shift the
immune responses to Th1 pattern and cause a better outcome in terms of tumor progress and survival rate.
E-mail: mh-yazdi@tums.ac.ir